Estrogen plus progestin reduced risk for fracture in postmenopausal women

May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p61
Academic Journal
This article focuses on the role of estrogen plus progestin to reduce the risk for fracture in postmenopausal women. Analysis was by intention to treat. Fewer women in the hormone therapy group than in the placebo group had a fracture. The effect for total fracture risk remained constant across different subgroups. When treatment effects on other important outcomes were included in a global model, hormone therapy had no net benefit, even in women with high risk for fracture. In a global model assessing treatment effects on all outcomes, hormone therapy had no net benefit.


Related Articles

  • Oestrogen plus progestin reduced risk of fracture in postmenopausal women. Cauley, J. A.; Robbins, J.; Chen, Z. // Evidence Based Medicine;May/Jun2004, Vol. 9 Issue 3, p82 

    The article discusses effects of oestrogen plus progestin in reducing the risk of fracture in postmenopausal women. Women above 50 and an intact uterus in the hormone therapy group than in the placebo group had a fracture. The effect of total fracture risk remained constant across different...

  • Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women. Chlebowski, Rowan T.; Wactawski-Wende, Jean; Ritenbaugh, Cheryl; Hubbell, F. Allan; Ascensao, Joao; Rodabough, Rebecca J.; Rosenberg, Carol A.; Taylor, Victoria M.; Harris, Randall; Chen, Chu; Adams-Campbell, Lucile L.; White, Emily // New England Journal of Medicine;3/4/2004, Vol. 350 Issue 10, p991 

    Background: Although the Women's Health Initiative (WHI) trial of estrogen plus progestin in postmenopausal women identified more overall health risks than benefits among women in the hormone group, the use of estrogen plus progestin was associated with a significant decrease in the risk of...

  • HRT does not prevent heart disease. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);8/16/2003, Vol. 327 Issue 7411, p359 

    Discusses how hormone replacement therapy (HRT) does not prevent coronary heart disease. Consideration of a medical trial that compared the combined estrogen and progestogen treatment with placebo; Risk of myocardial infarction and death in women who were given a placebo; Role of oestrogen in...

  • Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors. Guerrero-Zotano, Angel; Muggia, Franco // Current Cancer Therapy Reviews;2010, Vol. 6 Issue 1, p51 

    Treatment options for hormone-dependent advanced breast cancer (BC) have evolved from surgical oophorectomy, first proposed over a century ago. The discovery of steroid hormones, steroid hormone receptors and the concept that inhibition of steroid biosynthesis or hormone receptor blockade...

  • Timing of follow-up densitometry in hormone replacement therapy users for optimal osteoporosis prevention. Checa, Miguel A.; Rio, L. Del; Rosales, J.; Nogués, X.; Vila, J.; Carreras, R. // Osteoporosis International;Aug2005, Vol. 16 Issue 8, p937 

    The objectives of the study were (1) to determine the time interval for repeat dual-energy X-ray absorptiometry (DXA) to detect significant bone loss, i.e., greater than the coefficient of variation (CV) of the center (2.8 × CV%) and (2) to assess how long hormone replacement therapy can be...

  • Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Meyer, H. E.; Lofthus, C. M.; Søgaard, A. J.; Falch, J. A. // Osteoporosis International;May2009, Vol. 20 Issue 5, p827 

    Fracture incidence in Oslo decreased from the 1970s to the 1990s in younger postmenopausal women, but not in older women or in men. Concurrently, hormone replacement therapy increased considerably. Using data from the Oslo Health Study, we estimated that roughly half the decline might be...

  • Desperately Seeking a Reason to Keep Women on Hormones --New Trial Planned. Napoli, Maryann // HealthFacts;May2004, Vol. 29 Issue 5, p3 

    Provides information on the Women's Health Initiative, a government-funded clinical trial in the U.S. in which healthy postmenopausal women had been randomly assigned to take hormones or a placebo. Reason behind the suspension of the initiative in 2002; Effect of taking an estrogen and...

  • Which postmenopausal women should be offered combined HRT? Oliver, M. Norman; Sheufelt, Janice; Deshpande, Prajakta; Grandage, Karen K.; St. Anna, Leilani // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p149 

    The article talks about the adverse effects of hormone replacement therapy (HRT) on postmenopausal women including cardiovascular disease, thromboembolic disease and breast cancer. The Women's Health Initiative randomized trial of HRT on the use of estrogen plus progestin for prevention of...

  • Combined HRT improves HRQOL in older women.  // PharmacoEconomics & Outcomes News;9/6/2008, Issue 561, p8 

    The article focuses on the capability of combined hormone replacement therapy (HRT) to improve health-related (HR) quality of life (QOL) in women who begin treatment years after menopause, based on research. The postmenopausal women who participated in the study were from general practices in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics